SITC Cancer Immunotherapy CONNECT

2021 SITC Logo Crop

Access SITC 2021 Enduring Materials

You can now access SITC 2021 Enduring Materials on SITC CONNECT. Attendees will continue to have complimentary access to materials* and programs originally registered for, non-registrants can purchase content* for 50% off program registration rates.

*As permitted by presenters.

 

2022 TME

Tumor Immune Microenvironment:

A Holistic Approach Hybrid Workshop
This workshop will focus on the tumor microenvironment and its possible impact on the development of future immunotherapies.

aci17-cmyk.png
Log in to an upcoming Advances in Cancer Immunotherapy™ Live Virtual Program!
Jan. 27 ACI: A Focus on Intratumoral Therapies, Vaccines, and Cytokines

Feb. 2 ACI: Hematologic Malignancies
Feb. 10 ACI: A Focus on Monoclonal Antibodies and Antibody Drug Conjugates

Feb. 24: A Focus on Skin Cancers

LEARN MORE

SITC CIG App Homescreen Cropped

Download the new SITC Clinical Practice Guidelines (CPG) Mobile App!
The first and only immunotherapy-specific clinical practice guidelines app featuring guideline content and expert panel recommendations in an easy-to-navigate format. The app includes interactive tools, bookmarks, and advanced search capabilities.
Available for FREE for iOS and Android.

Learn More




Winter_School.png

Cancer Immunotherapy Winter School, Jan. 24–28, 2022

SITC is pleased to host its fourth annual and first hybrid Cancer Immunotherapy Winter School, a comprehensive cancer immunotherapy education program, Jan. 24–28, 2022.

Register Today

New SITC Clinical Practice Guidelines Published

  • Acute Leukemia
  • Breast Cancer
  • Hepatocellular Carcinoma
  • Immune Checkpoint Inhibitor-related Adverse Events
  • Urothelial Cancer
Free companion educational webinars available.


jitc-cmyk.jpg

JITC Increases Impact Factor to 13.751
The Journal for ImmunoTherapy of Cancer's (JITC) Impact Factor makes JITC the highest ranked fully open access immunology journal and places it in the top 5% percent of all journals published in the category of immunology and top 7% in the category of oncology.

JITCREVIEW.png

JITC Special Series: COVID-19 and Cancer Immunotherapy

Comprised of several authoritative reviews of COVID-19 and Cancer Immunotherapy, this series, edited by Paolo Antonio Ascierto, MD and Jason D. Goldman, MD, MPH, will explore basic insights into the immunology of the novel coronavirus, repurposing of immune-based therapies including the effects of immune-oncology agents, and the affected cancer populations.

20-WhyMem-v152.jpg

Why I'm a SITC Member

Join Alan Hutson, PhD, and the thousands of other cancer immunotherapy professionals who proudly call themselves SITC members.

Become a SITC Member

Consistent with the Safer at Home Order issued by the Department of Health Services of the State of Wisconsin, all SITC Executive Office staff will be working remotely beginning March 25, 2020, and are best reached through email. General inquiries can be sent to info@sitcancer.org. Thank you for understanding.

Patient

Explore resources and educational opportunities for cancer patients and those who advocate for them.

Explore

 

 

 

 

Clinician

Track the latest advancements and educational opportunities in tumor immunology and cancer immunotherapy.

Explore

 

 

 

 

Researcher

Advance science, submit your manuscript and monitor the global progress of cancer immunotherapy research.

Explore

 

 

 

 

Latest Discussions

  • As research of cancer immunotherapy, and clinical use of these treatments, continues to grow, so too does the importance of clinicians sharing experiences and learning from others. We hope this community will afford you the opportunity. ------------------------------ ...

  • Posted in: Women in SITC

    I wanted to remind my fellow community members that SITC is hosting the 2022 Cancer Immunotherapy Winter School in Austin, TX on Jan. 24–28, 2022 both in person and virtually. The Winter School , organized by Catherine Bollard, MBChB, MD, Christian ...

  • Posted in: Women in SITC

    Sharing opportunities for all whom might be interested: The Cancer Research Institute is requesting applications for the Lloyd J. Old STAR Program . The STAR Program- S cientists TA king R isks-provides long-term funding to mid-career scientists, ...

Follow the SITC Twitter Feed.

 

Connect with colleagues at these Upcoming Events.

 

Ignite the SITC Sparkathon

Donate today to support early career scientists who are emerging leaders seeking to advance research in the cancer immunotherapy field.

 

Learn More

 

The Journal & The Blog

Journal for ImmunoTherapy of Cancer

An open access, peer-reviewed journal, the Journal for ImmunoTherapy of Cancer (JITC) is the global voice of the society, producing original research articles, literature reviews and more on tumor immunology and cancer immunotherapy.

Learn More

 

Making Cure a Reality

It is the mission of the Society for Immunotherapy of Cancer (SITC) to improve cancer patient outcomes by advancing the science, development and application of cancer immunology and immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.

 

Learn More